Transparency Market Research Report Added "Healthcare Associated Infections Treatment Market" to its database.
Albany, NY -- (SBWIRE) -- 11/28/2016 -- Healthcare-associated infections (HAIs) are the ones that are contracted by patients while they are receiving treatment for another medical condition in a healthcare setting. Thus HAIs can be acquired at any place where healthcare is delivered. HAIs are generally caused by infectious agents, pathogens, fungi, bacteria, and viruses. The risk factors associated with these infections are use of indwelling medical devices, surgeries, injections, contaminated healthcare environment, communication of diseases between workers and patients, and improper use of antibiotics.
Read Full Report: http://www.transparencymarketresearch.com/healthcare-associated-infections-treatment.html
HAIs are a major cause of mortality and morbidity on a worldwide scale. Each year HAIs lead to thousands of deaths. A majority of HAIs include conditions such as urinary tract infections, surgical site infections, bloodstream infections, gastroenteritis, and pneumonia. The overall HAI treatment market can be classified on the basis of devices and pharmaceuticals used for HAI treatment. The major pharmaceuticals used in HAI treatment are viral pharmaceuticals, bacterial pharmaceuticals, and fungal pharmaceuticals. The major drug classes used in the pharmaceuticals segment are B-Lactam Antibiotics, cephalosporins, quinolones, glycopeptides, lincosamides, polypeptides, carbapenems, lipopeptides, penicillins, macrolides, tuberculosis, etracyclines, sulfonamides, and other such formulations. The medical devices segment can be further categorized into catheters and ventilation devices and in-line sterile IV filtration.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1223
The U.S. is the largest market for HAI treatment pharmaceuticals and devices. In the U.S., each year more than 1.5 million patients contract HAI. Recently Partners for Patients had introduced a USD 500 million grant to help hospitals and other healthcare providers to reduce HAIs in the U.S. it is expected that if successful, this program will save USD 50 billion of U.S. Medicare over the next ten years. The other markets for HAI treatment devices and pharmaceuticals are Asia-Pacific, Europe, and the Rest of the World. Some of the major players of this market include companies such as Merck, Johnson & Johnson, GlaxoSmithKline, Sharklet Technologies, Ondine Biomedical and some others.
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453